Sep 8, 2017

University of Florida Researchers Working to Develop New Sepsis Treatment

By on 6:21 AM

Researches from the University of Florida are participating in a clinical trial that evaluates whether an anti-cancer medication can serve as an effective treatment for sepsis and septic shock, according to a UF report.

Sepsis is the body's extreme response to an infection. It is life-threatening, and without timely treatment can rapidly cause tissue damage, organ failure and death.

Researchers are working to determine whether an immunotherapy drug used to treat patients with types of non-small cell lung cancer and other variants of the disease can also treat sepsis patients. The drug blocks a protein, which then boosts the immune system.

As data from the Agency for Healthcare Research and Quality notes, sepsis (septicemia) was the most expensive condition treated in U.S. hospitals in 2013, accounting for nearly $24 billion in aggregate hospital costs. This is more than $7 billion higher than the second most expensive condition treated (osteoarthritis).

The clinical trial involves organizations from throughout the country. The report indicates that UF is the only center in Florida recruiting participants for the trial at this time.

Phenelle Segal, RN, CIC, FAPIC

Phenelle Segal, RN, CIC, FAPIC, is the founder and president of Infection Control Consulting Services LLC (ICCS), which is based in Delray Beach, Florida. Phenelle has more than 30 years experience providing customized comprehensive infection control and prevention services to healthcare facilities nationwide. Her services focus on assisting hospitals, ambulatory surgery centers, dental office and oral surgery practices, doctor's offices, nursing homes to implement and maintain an infection control program that: complies with The Joint Commission (TJC), Centers for Medicaid and Medicare Services (CMS) and other regulatory agencies, respond to situations of noncompliance, and improve the processes for reducing risk.


Post a Comment